DarshanTalks Podcast

Send us Fan Mail

On Friday, the Trump administration announced a 15% cap on NIH indirect costs, raising important questions about its impact on research funding. Edye Edens breaks down what this means, clarifying that while direct costs like salaries and equipment remain unchanged, the cap affects crucial behind-the-scenes expenses such as lab maintenance, IT infrastructure, cybersecurity, and compliance. Understanding these distinctions is key as institutions adapt—watch as Edye unpacks the details.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The Trump administration’s actions have effectively halted USAID-funded clinical research worldwide, creating an unprecedented situation with significant ethical, legal, and medical implications. Clinical trials that relied on USAID funding have stopped, leaving ongoing research in limbo and raising serious concerns about what happens to trial participants and who bears responsibility for any resulting harm.

Key Legal and Ethical Questions:

1. Who is the sponsor?

If the U.S. government was the official sponsor of a trial, sovereign immunity could come into play. This legal doctrine generally protects governments from being sued unless they explicitly waive immunity. Whether the U.S. government would assert sovereign immunity in this situation remains unclear.

2. Can individuals be held responsible?

Legal action against government officials, including former President Trump and members of his administration, would depend on whether they were acting in their official capacities. If they were, they may be shielded from personal liability.

3. What about pharmaceutical companies?

If a trial was co-funded by multiple entities—such as the NIH, USAID, and a private pharmaceutical company—the company might still bear responsibility. The extent of its liability would depend on contractual agreements, funding structures, and trial oversight mechanisms.

This situation is virtually without precedent, making it difficult to predict outcomes. However, if trial participants suffer harm due to halted research, legal action is almost certain. The coming months may bring lawsuits, debates over liability, and broader discussions about the role of government funding in global clinical research.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

On January 30, 2025, Uganda confirmed an outbreak of the Ebola Sudan virus, and in an unprecedented global first, a clinical trial to assess the efficacy of a vaccine against the virus was launched within just four days. This rapid response was made possible by proactive planning following a 2022 outbreak, during which the Ugandan Ministry of Health, Makerere University, and the Uganda Virus Research Institute implemented a strategy to fast-track future trial activations. By pre-selecting investigators, securing protocol approvals, and ensuring regulatory readiness, they positioned themselves to immediately initiate the trial once a new outbreak emerged. With WHO’s support, this initiative represents a groundbreaking moment in clinical research—offering real-time data collection during an active outbreak while potentially saving countless lives. The WHO’s press release details the extensive collaboration and meticulous groundwork that made this possible, reinforcing the importance of preparedness in global health crises.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

When working on an M&A transaction involving a clinical trial site, it's crucial to thoroughly review vendor agreements. It's not just about what is included, but what is missing. For example, do you have the right quality and privacy agreements in place, or are you unknowingly exposing yourself to liability? If there’s a lack of necessary agreements, it’s important to assess whether it’s due to ignorance or an oversight that could lead to future legal risks. If you're unsure, reach out to ensure you're on the right track and avoid unnecessary liabilities.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The most recent ICH E6(R3) final guidance introduces critical updates to Good Clinical Practice (GCP), particularly around informed consent and participant data access. The guidance emphasizes greater flexibility and the use of technology-driven innovations to enhance how patients understand what they are consenting to.

A significant update appears in section 2.8 (Investigator Responsibilities), which now requires a clear plan for returning trial-related data to participants when appropriate. This shift acknowledges the growing importance of transparency and participant rights in clinical trials. However, the guidance does not explicitly assign this responsibility to sponsors, despite them often being the ones who restrict access to participant data. While this change is a major step forward in ethical research practices, its practical enforcement remains uncertain without direct sponsor obligations.

These updates reflect a broader shift toward patient-centric clinical trials, but questions remain about how effectively they will be implemented.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Now that we’ve passed February 1st, a key date for the potential easing of the freeze on all HHS communications, we find ourselves at February 3rd with no significant updates or changes. Despite expectations that restrictions might begin to lift, there has been no broad release of communications across federal agencies involved in clinical trials and regulatory oversight. While this does not provide definitive insight into the administration’s plans, it does confirm that, for now, the freeze remains in place.

A critical concern emerging from this situation is the growing tendency of certain federal agencies to offer guidance on behalf of others. While this may be well-intentioned, it presents a risk for those in regulatory and research compliance. Some professionals are now uncertain about whether to report specific matters to Agency A, B, or C, given that the usual communication channels remain restricted. In some cases, agencies that are not the primary governing bodies for certain regulatory matters are advising stakeholders on reporting requirements, creating potential compliance pitfalls.

It is essential to recognize that no directive has been issued allowing agencies to speak on behalf of one another. If an agency suggests a course of action based on its assumptions about another agency’s stance, this does not guarantee compliance. Any decision based on such unofficial guidance could lead to regulatory missteps.

In light of this uncertainty, professionals should exercise extreme caution. For any matters related to patient safety or immediate harm, necessary clinical actions should be taken without hesitation, with follow-up reporting to the appropriate governing body as soon as possible. However, for proactive regulatory filings or compliance-related decisions that do not require urgent action, it may be prudent to wait for official guidance once communication channels reopen.

As the situation develops, we encourage industry professionals to stay informed and connected. Continue monitoring updates from KLF for the latest insights and recommendations on navigating regulatory challenges during this period of restricted federal communication. If you have specific concerns, feel free to reach out for further guidance.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions about safety, ethics, and the future of healthcare, with both promise and complexity.

One of the most well-known examples is Lorenzo’s Oil, where Michaela and Augusto Odone developed a treatment for their son Lorenzo, who was diagnosed with a rare and fatal genetic disorder. Their research and persistence led to a groundbreaking treatment that helped slow the disease's progression. Another inspiring story is that of Dr. David Fajgenbaum, who, after being diagnosed with Castleman’s disease, repurposed existing drugs to stabilize his condition, saving his life and offering hope to others. These remarkable examples demonstrate how determination and innovation can lead to life-saving breakthroughs.

However, citizen biohacking raises crucial concerns, such as safety and ethics. Operating outside the traditional medical system, it challenges regulatory bodies to reconsider how innovation is validated and tested. Despite these challenges, citizen biohacking is changing the landscape of medicine, pushing the medical community to think differently, adapt more quickly, and collaborate with unconventional innovators. If you’re interested in exploring these stories and the legal implications of this trend, tune in to our Darshan Talks podcast or reach out to Kulkarni Law Firm for expert guidance. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is that the federal communication freeze across health agencies is expected to ease by February 1, which should provide more clarity on the administration’s direction.

However, concerns have emerged regarding a significant halt in NIH funding, disruptions in scheduled meetings for ongoing and proposed trials for 2025, and the removal of publicly posted regulations related to diversity initiatives. While some argue these policies were not strongly enforced previously, their sudden absence raises uncertainty about future regulatory actions.

On a positive note, research that had been previously approved and grandfathered in is allowed to continue despite the communication freeze. At KLF, we are closely monitoring these developments, analyzing the latest updates, and advising our clients on navigating these evolving challenges. While uncertainty remains, no news is not necessarily bad news, and we are committed to keeping our clients informed and compliant. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

When selling a company, certain issues may arise that could concern potential buyers. Here's a breakdown of how to approach them:

1. Price Adjustments: Some issues can be acknowledged, and the buyer may adjust the price accordingly, allowing the sale to proceed with minimal adjustments.
2. Successor Liability: Issues like DOJ concerns or successor liability might require more attention, especially in asset-based transactions.
3. Risk-Based Analysis: For less critical matters, such as design defects, you might decide to accept the risk if the buyer is comfortable with it.
4. Critical Issues: If the problem involves patient safety or legal compliance, it’s best to resolve it before proceeding with the sale.
5. Buyer Acceptance: If the buyer is willing to take on certain risks, no action may be required, but other times, it's vital to address issues upfront.

If you're navigating this process, getting the right advice is essential. Reach out to us for guidance on how to handle these complexities.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni and Edye Edens discuss the latest update to Good Clinical Practice (GCP) guidelines, E6 R3, was explored. GCP, developed by the International Council for Harmonisation (ICH), provides globally accepted ethical and operational standards for conducting clinical trials. The 2025 update represents a significant revision since its last update in 2016, emphasizing technology, data integrity, and structural changes to accommodate rapid innovation in clinical research.

Key Highlights of E6 R3:

1. Focus on Technology and Data Integrity:
   
   
   
   • A new section on data integrity outlines requirements for technology validation, metadata handling, and data protection.
   • Emphasizes maintaining data accuracy and security throughout the clinical trial process.
2. Roles and Responsibilities:
   
   
   
   • Clearer delineation of sponsor and investigator duties.
   • Sponsors retain responsibility for vendor oversight, even when authority is delegated.
3. Quality by Design and Risk-Based Quality Management:
   
   
   
   • Greater emphasis on integrating quality principles from the conception of trials through to completion.
   • Risk-based approaches to monitoring focus on proportional oversight based on trial risk levels.
4. Patient-Centric and Ethical Focus:
   
   
   
   • Includes considerations for participant confidentiality, returning trial results to participants, and respecting participants as central to the process.
   • Promotes trial design and oversight that prioritize participant safety and data reproducibility.
5. Harmonization and Enforcement:
   
   
   
   • While GCP is an ethical doctrine rather than a law, compliance is often contractually required by sponsors and regulatory bodies like the FDA.
   • FDA has increasingly integrated GCP compliance into its expectations for U.S. clinical trials.

Implications for Stakeholders:

• Sponsors, investigators, and sites must adapt to heightened expectations for data handling, quality management, and documentation.
• Organizations should prepare for potential changes in monitoring and auditing practices, with risk-based methodologies becoming more prevalent.

This update underscores the importance of staying informed about evolving guidelines to ensure compliance, safeguard participant rights, and maintain trial integrity. Stay tuned for more insights and discussions on navigating these changes effectively.

Support the show

www.kulkarnilawfirm.com